The company expects to receive about $725,200 after sales commission and other expenses...UMN Pharma Inc., of Akita, Japan, and Catalent Pharma Solutions, of Somerset, N.J., signed a deal in which Catalent will provide UMN a broad range of biosimilar cells lines using its GPEx technology

In a flash note, she observed that, with respect to pharmacokinetics, "it's unclear whether PI3K gamma inhibition by IPI-145 has meaningful contribution to anticancer activity...OncoSec plans to use the proceeds to fund clinical trials and research and development and for other corporate purposes...The company plans to use the proceeds to fund research and development, clinical trials and for other corporate purposes.

Galderma Pharma SA, of Lausanne, Switzerland, agreed to acquire Spirig Pharma AG, of Egerkingen, Switzerland

Eisai has a pending new drug application for Aciphex delayed-release sprinkle capsules 5 mg and 10 mg for the proposed indication of gastroesophageal reflux disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children, ages 1 to 11

Earlier this year, the company inked a potential $33 million strategic alliance with Mitsubishi Tanabe Pharma Corp., of Osaka, Japan, to develop and commercialize at least three vaccines using the VLP technology. (See BioWorld Today, March 7, 2012...Shares of Somaxon (NASDAQ:SOMX) soared on the buyout news, gaining 80.3 percent, or $1.18, to close Tuesday at $2.65. (See BioWorld Today, March 19, 2010, July 16, 2010, Aug. 26, 2010, and June 9, 2011...Ltd., pursuant to the existing license

Distribution of Prothena ordinary shares in the demerger is conditioned upon, among other conditions to the demerger, a registration statement filed with the SEC, having been declared effective by the SEC and the affirmative vote of the Elan shareholders...Galderma Pharma SA, of Lausanne, Switzerland, and Valeant Pharmaceuticals International Inc., of Montreal, reached agreement on terms of a revised North American aesthetics arrangement, resolving Galderma's pending litigation related to Valeant's

GlaxoSmithKline plc, of London, and the Fred Hutchinson Cancer Research Center entered a partnership to develop therapeutics to treat an inherited form of muscular dystrophy...The goal of the agreement is to develop a small-molecule-based medicine to potentially reverse facioscapulohumeral muscular dystrophy by inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene in people with the disease

Akela Pharma Inc., of Vancouver, British Columbia, said its voluntary delisting from the Toronto Stock Exchange occurred at the close of trading Dec. 7...Payments to Isis could total $200 million, including license fees and regulatory milestones per program, plus additional double-digit royalties...Geron agreed to assign to TA Sciences Inc., of New York, those patents previously licensed to Asia Biotech, including intellectual property relating to telomerase activation technology

Reddy's Laboratories Ltd., of Hyderabad, India, acquired exclusive marketing and sales rights to Pamorelin LA (triptorelin) Depot, by Debiopharm Group, of Lausanne, Switzerland, in India for locally advanced or metastatic, hormone-dependent prostate cancer

Janssen Biotech Inc., of Horsham, Pa., and Janssen Biologics B.V., of Leiden, Netherlands, both part of Johnson & Johnson, submitted a supplemental biologics license application (sBLA) to the FDA and a Type II Variation to the European Medicines Agency (EMA) requesting approval of Stelara (ustekinumab) to treat adult patients with active psoriatic arthritis...The FDA gave guidance and permission to Lipocine Inc., of Salt Lake City, for its Phase III study of oral testosterone replacement therapy

Preclinical treatment goals for the TNBC and IBC indications are two-pronged: as a tumor reduction agent in combination with other approved drugs in preoperative settings and as a drug to treat and control or eliminate cancer metastasis in TNBC and IBC patients...Distribution of Prothena ordinary shares in the demerger is conditioned upon, among other conditions to the demerger, a registration statement filed with the SEC, having been declared effective by the SEC and the affirmative vote of the

Astellas Pharma Inc., of Tokyo, said the FDA accepted for review its new drug application for tacrolimus extended-release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients

The product is designed to treat chronic diabetic macular edema considered insufficiently responsive to available therapies...Apexigen Inc., of Burlingame, Calif., signed a manufacturing supply agreement with Boehringer Ingelheim GmbH, of Ingelheim, Germany, under which the big pharma firm will provide cell line development with the high expression BI-HEX system, full process and method development, scale-up and clinical Phase I supply for APX005, a humanized monoclonal antibody designed to target

In other news, Bayer said its BAY 86-6150 is being investigated in a Phase II/III study, dubbed TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete...In other news, Viralytics is offering shareholders up to $15,000 worth of shares at 30 cents each in a new underwritten share purchase plan to fund the company's intravenous cancer trial and the continued clinical research and development of Cavatak, its lead oncolytic virus candidate

Ipsen SA, of Paris, and Galderma Pharma SA, of Lausanne, Switzerland, said they extended their collaboration for the promotion and distribution of Dysport, Ipsen's botulinum toxin Type A in aesthetic indications, renewing the deal in Brazil and Argentina and adding Australia where Galderma has the exclusive promotion and distribution rights for Dysport in the glabellar lines indication

Eisai Inc., of Woodcliff Lake, N.J., said the FDA accepted for priority review Eisai's NDA for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of gastroesophageal reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age

The news came late Thursday, shortly after the company disclosed FDA approval of Cometriq in MTC...Isotechnika Pharma Inc., of Edmonton, Alberta, said a partial award has been issued in the company's ICC arbitration regarding its right to terminate the development, distribution and license agreement with Iljin Life Sciences Co

Details Date Advaxis Inc. (Princeton, N.J.) Private placement N/A $10 Advaxis secured $10M in equity financing from Magna Group LLC 11/1/12 Amarantus BioSciences Inc. (Sunnyvale, Calif.) Private placement N/A $1.1 Amarantus secured $1.1M in funding through two separate transactions, by issuing a convertible promissory note to an undisclosed investor in the principal amount of $600,000 and, with an institutional fund, settled more than $500,000 in accounts payable 11/15/12 Ambit Biosciences Inc

After the dividend distribution, expected to be paid Jan. 1, 2013, AbbVie will be an independent, publicly traded company, and Abbott will retain no ownership interest...AbbVie common stock is expected to begin trading Jan. 2, 2013, on the New York Stock Exchange under the ticker "ABBV...The recall does not affect or related to the 80-mg dosage strength of the cholesterol-lowering drug